{
    "context": "[6] In total, there were 18 patients (40%) with limited/locally advanced disease (stages IB-IIIB) and 27 patients (60%) with extensive/metastatic disease (stage IV). [7] Patients with current or recent infections/sepsis were not recruited to prevent any confounding effect of inflammation, nor were patients with comorbidities such as diabetes mellitus, immune-related diseases, liver disorders or other malignancies. [1] EBC was collected according to standard procedures (EcoScreen; Viasys, Hoechberg, Germany). [2] 8-Isoprostane concentration in EBC was determined by a specific enzyme immunoassay kit (8-Isoprostane EIA Kit \u00e2\u20ac\u201c Cayman Chemicals, Ann Arbor, MI, USA). [3] The detection limit of the assay was 2.7 pg/ml. [1] All patients underwent first EBC collection prior to the initiation of any treatment, while a second EBC sample was performed after the completion of the sixth cycle of chemotherapy (platinum or taxane-based). [2] EBC was obtained from patients without consumption of food, drinks or cigarettes for at least two hours prior to sampling. ",
    "term_A": "8-epi-PGF2alpha",
    "term_B": "Chemicals",
    "llm_generation": {
        "summary": "In this context, 8-epi-PGF2alpha is mentioned as a specific biomarker measured in exhaled breath condensate (EBC) using an enzyme immunoassay kit. While it is categorized under chemicals due to its biochemical nature, the relationship is primarily focused on its role as a marker rather than a direct interaction with other chemicals. The context does not elaborate on how 8-epi-PGF2alpha interacts with other chemicals or its broader implications in the study.",
        "reason": "The score of 2 reflects an indirect connection, as 8-epi-PGF2alpha is classified as a chemical and is measured in the study, but there is no detailed discussion of its interactions or significance with other chemicals.",
        "score": 2
    }
}